Sprycel recognized as essential medicine

Published: 2008-01-15 06:57:00

Updated: 2008-01-15 06:57:00

BMS Korea says its Sprycel (dasatinib), an oral inhibitor of multiple tyrosine kinases, has been recommended for use as one of essential medicines from the national deliberation committees consisting of oncologists.

Dasatinib is approved for the treatment of adults with chronic, accelerated or...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK